Today: 19 May 2026
Innoviz Stock Skyrockets on LiDAR Boom and Big Autonomous Driving Deals
15 October 2025
3 mins read

Innoviz Stock Skyrockets on LiDAR Boom and Big Autonomous Driving Deals

  • Price surge: INVZ traded around $2.38 as of mid-Oct 2025 , up ~29% in the last month and 219% year-over-year . (One-day gain on Oct.14 was +9.2%.)
  • Market cap & targets: Market cap is roughly $438M . Analysts’ 12‑month consensus price target is about $3.27 (≈+37% upside) ; the consensus rating averages between Hold and Strong Buy.
  • Financial results & guidance: Q2 2025 revenues were $9.7M (vs $6.7M YoY) , with record H1 revenues exceeding all of 2024 . Innoviz reiterated its FY2025 sales guidance of $50–60M and raised its 2025 non-recurring engineering (NRE) bookings target to $30–60M . (Cash burn in Q2 was reduced to single digits .)
  • Major contracts: Innoviz has landed multiple high‑profile design wins. A “Top‑5” passenger car OEM signed a development deal for InnovizTwo LiDAR on a Level-3 vehicle (SOP 2027) ir.innoviz.tech. A leading Class-8 truck maker selected InnovizTwo for future Level-4 autonomous trucks ir.innoviz.tech. (Volkswagen’s MOIA already uses Innoviz for its ID.Buzz L4 shuttle prnewswire.com.)
  • Strategic partnerships: The company is expanding beyond vehicles. It teamed with Cron AI and D2 Traffic to deploy LiDAR at smart intersections , and with Cogniteam (Italy) to offer a 400m-range InnovizSMART security/AI solution . Other collaborations include Sparsh CCTV for Indian transit and NVIDIA integration for InnovizSMART.
  • Product/certification updates: In June 2025 Innoviz launched InnovizSMART, a long-range LiDAR (400m) built on its auto-grade tech for industrial and smart‑city applications . On Sept. 30 it earned ISO/IEC 17025:2017 accreditation for its hardware testing labs , enabling faster in‑house qualification of LiDAR components.
  • Industry context: The global LiDAR market is booming. About 1.6 million LiDAR units shipped in 2024 (over double 2023 levels) , and forecasts project ~25% annual growth, reaching ~$10B by 2033 . Chinese EV makers dominate the space: in 2024 Chinese firms accounted for ≈93% of automotive LiDAR unit volume (Hesai ~33% share) . (By contrast, Western OEMs mostly reserve LiDAR for premium models and robo-taxis .)

Innoviz’s recent stock surge reflects these positive fundamentals. CEO Omer Keilaf emphasized in the Q2 report that “we generated more revenues than in all of 2024” in H1 and drove cash burn into low single digits ir.innoviz.tech. He noted Innoviz has begun shipping units from its new Fabrinet production line and is advancing its L3 and L4 programs. Keilaf also highlighted the InnovizSMART product, calling it “built on the same technological foundation as [our] automotive solutions” for smart infrastructure ts2.tech. These comments underscore that Innoviz is not only growing sales but also diversifying into security, traffic and robotics markets.

Analysts agree growth is accelerating. A Goldman Sachs analyst (Mark Delaney) upgraded INVZ to Buy in late Sept. 2025, lifting his price target to $2.50. Delaney cited an influx of design-win opportunities and noted Innoviz trades at a discount to peers benzinga.com. He argued that as “autonomous driving technology becomes increasingly important for automakers, new advanced driver-assistance and autonomous vehicle program awards should accelerate” benzinga.com. Delaney pointed to Innoviz’s programs with a top-five automaker and a Class‑8 truck OEM as evidence that the company could soon secure series-production contracts benzinga.com. In his models, Innoviz revenue could reach about $150M by 2028 under current plans, with upside toward $250M if AV adoption rises faster benzinga.com. (He projects 2028 EBITDA breakeven in his base case.)

Other experts highlight the broader market tailwinds. An industry analyst noted that ≈40 auto OEMs were using LiDAR by 2024 (up from 8 in 2021) – most of them in China wevolver.com. With camera and radar technologies advancing, Tesla famously eschews LiDAR; but others like Ford have openly endorsed LiDAR as “critical for safety” in self-driving ts2.tech. Innoviz’s use of 905-nm laser technology (safer for eyes/cameras than 1550-nm beams) has also drawn interest amid recent headlines about Luminar’s 1550-nm units damaging camera sensors designnews.com.

On valuation, Innoviz still trades at a high ratio – around 12.7× price-to-sales simplywall.st, reflecting expectations of rapid growth. The company’s cash reserves (~$79M at Q2-end ir.innoviz.tech) and milestone bookings provide a buffer while it executes on its roadmap. The upcoming Q3 results (due Nov. 12, 2025 stockanalysis.com) will be closely watched for progress on these fronts. In summary, while INVZ remains a speculative small‑cap, its recent momentum is backed by concrete wins and a booming LiDAR market. As one analyst put it, Innoviz’s blend of “strong customer engagement and units now shipping from our high-volume manufacturing line” suggests it’s on track to capitalize on the surge in autonomous-vehicle technology ir.innoviz.tech benzinga.com.

Sources: Innoviz press releases and filings ; financial news reports and analyses ; stock data (Yahoo/Investing) .

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • ASX Set to Rise on Oil Price Drop and Trump Iran Strike Delay; Technology One Reports Higher H1 Earnings
    May 18, 2026, 9:07 PM EDT. Australian shares are expected to rise Tuesday as oil prices eased and global markets steadied. The market reaction follows US President Donald Trump's postponement of a planned strike on Iran, reducing geopolitical risk. In corporate news, Technology One reported increased earnings and revenue for the first half of its fiscal year, signaling investor confidence in the tech sector. The combination of calmer oil markets and solid corporate earnings underpins the positive outlook on the Australian Securities Exchange (ASX) today.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears
Previous Story

Nuclear SPAC Stock Skyrockets on Merger Frenzy: HOND Shares Soar as Terrestrial Energy Deal Nears

NUAI Stock Rockets 85% on AI Data Center News – Is the Rally Sustainable?
Next Story

NUAI Stock Rockets 85% on AI Data Center News – Is the Rally Sustainable?

Go toTop